Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03787225 · ClinicalTrials.gov registry record · Phase 1

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

A Phase 1 study, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 1
Development phase
66
Enrollment target

NCT03787225 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03787225, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 1
Development phase
66 participants
Enrollment target

Study Summary

The aim of this study is to look at how the study medicine behaves in the participant's body and how it is removed from the participant's body. The study compares Japanese and Caucasian people who are normal weight, overweight or with obesity. The participants will either get NNC0174-0833 (a potential new medicine) or placebo (a "dummy" medicine similar to the study medicine but without active ingredients) - which treatment any participant gets is decided by chance. Participants will get 1 injection by a study nurse at the clinic. The injection will be with a needle in a skin fold in the participant's stomach area. The study will last for about 4 months, but duration of participation for any participant will last up to about 2 months. The participants will have 8 clinic visits with the study staff.

Interventions

  • DRUG NNC0174-0833
  • DRUG Placebo (NNC0174-0833)

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2019-01-07
Est. Completion 2019-06-04
Phase Phase 1

Sponsor

Novo Nordisk A/S

431 total trials

What the Registry Record Tells You About NCT03787225

The ClinicalTrials.gov registry entry for NCT03787225 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which NNC0174-0833 is the first listed.

NCT03787225 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03787225 about?

NCT03787225 is a clinical study titled "A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity". The aim of this study is to look at how the study medicine behaves in the participant's body and how it is removed from the participant's body. The study compares Japanese and Caucasian people who are normal weight, overweight or with obesity. The participants will either get NNC0174-0833 (a potenti...

What is the current status of trial NCT03787225?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2019-01-07. Estimated completion is 2019-06-04.

What interventions are being tested in trial NCT03787225?

The interventions under investigation include: NNC0174-0833 (DRUG), Placebo (NNC0174-0833) (DRUG).

Who is sponsoring clinical trial NCT03787225?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.